CANTABio and Gardedam Therapeutics complete Merger to Tackle Development of Novel Therapeutics for Alzheimer's and Parkinson's Disease
December 21, 2015 13:00 ET
|
Cantabio Pharmaceuticals Inc.
PALO ALTO, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Cantabio Pharmaceuticals, Inc. ("Cantabio") (OTCQB:CTBO) is pleased to announce the completion of its reverse merger (the "Merger") with...
DiamiR Announces $1.5M SBIR Phase II Funding for Further Evaluation of the microRNA Biomarkers for Early Detection of Alzheimer's Disease
March 16, 2015 08:02 ET
|
DiamiR
MONMOUTH JUNCTION, NJ--(Marketwired - March 16, 2015) - DiamiR, LLC, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute...
DiamiR Announces Oral Presentation at the 2014 Alzheimer's Association International Conference
July 10, 2014 08:02 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - July 10, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring...
DiamiR Announces Presentation at the 2014 BIO International Convention
June 18, 2014 08:00 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - June 18, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring...
DiamiR Announces Poster Presentation on Detection and Differentiation of Neurodegenerative Diseases at the Biomarkers & Diagnostics World Congress 2014
April 28, 2014 08:00 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - April 28, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative blood-based...